Heartflow, Inc. Common Stock·Healthcare
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company's platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.
Healthcare
Medical - Healthcare Information Services
626
2025-08-07
1.03

Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow Platform

Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) insider Campbell Rogers sold 64,533 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.64, for a total value of $1,590,093.12. Following the sale, the insider owned 81,002 shares of the company's stock, valued at $1,995,889.28.

/PRNewswire/ -- USANewsGroup.com News Commentary - Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the

HeartFlow's chief medical officer exercised 67,017 options and sold 64,533 Common Stock shares on March 19, 2026, generating proceeds of about $1.66 million at an average price around $25.69 per share. The sale represented 22.36% of Campbell's direct common stock holdings at the time of the transaction.

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics to healthcare providers seeking advanced imaging and decision support tools.